Therapeutic Developability Analysis

Evaluating the developability of therapeutic drug candidates early can help circumvent potential issues in late-stage development. These evaluations include the drug candidate’s biophysical and chemical properties assessment. At LakePharma, in silico predictive tools and a series of fast & small-scale assessments are employed to serve as additional selection criteria for better and safe therapeutic leads.

LakePharma offers three developability assessment packages: 

 

Therapeutic drug developability assessment package 1 Therapeutic drug developability assessment package 2 Therapeutic drug developability assessment package 3

 

Key Highlights

 

In silico Analysis: Application of Bioinformatic Tools

•  Heavy and light chain variable region liability analysis
•  VH and VL analysis with identification of core residues with potential affinity to MHC class II

   

Rapid Integrity Assessments and Formulation Studies for Drug Candidates

•  Polyspecificity and integrity assessment can be completed in 2-3 weeks
•  Formulation studies can be completed in 5 - 6 weeks, including standard 2 weeks of incubation for accelerated stress conditions

   

Robust Bioanalytical Assays and Formulation Studies with Minimal Materials Required

•  Standard panel includes common formulations used for commercial antibodies
•  Various bioanalytical assays and characterization tools are provided
•  A small amount of materials are needed for the bioanalytical assays and formulation studies 

   
 Download Antibody Discovery brochure  View webinar: Discovery of Potent, Functional mAbs using Hybridoma and Phage Display Platforms
       

 

Please contact LakePharma at inquiries@lakepharma.com for custom quotes and details.

Cat.# Service Name Timeline Size Price Quantity Request
SKU-1000 Developability Package 1 Request Request Request
SKU-2000 Developability Package 2 Request Request Request
SKU-3000 Developability Package 3 Request Request Request